User profiles for J. Michot

Jean-Marie Michot

Gustave Roussy
Verified email at gustaveroussy.fr
Cited by 13990

[HTML][HTML] Immune-related adverse events with immune checkpoint blockade: a comprehensive review

JM Michot, C Bigenwald, S Champiat, M Collins… - European journal of …, 2016 - Elsevier
Cancer immunotherapy is coming of age; it has prompted a paradigm shift in oncology, in
which therapeutic agents are used to target immune cells rather than cancer cells. The first …

[HTML][HTML] Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper

…, J Le Pavec, E De Martin, C Mateus, JM Michot… - Annals of …, 2016 - Elsevier
Monoclonal antibodies targeted against the immune checkpoint molecules CTLA-4 and PD-1
have recently obtained approval for the treatment of metastatic melanoma and advanced/…

[HTML][HTML] Quinolones in 2005: an update

F Van Bambeke, JM Michot, J Van Eldere… - Clinical Microbiology …, 2005 - Elsevier
Quinolones are one of the largest classes of antimicrobial agents used worldwide. This
review considers the quinolones that are available currently and used widely in Europe (…

[HTML][HTML] Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure

…, JM Michot, PL Zinzani, J Kuruvilla… - Journal of Clinical …, 2016 - ncbi.nlm.nih.gov
Purpose Classical Hodgkin lymphoma (HL) frequently exhibits genetic alterations leading to
overexpression of the programmed death-1 (PD-1) ligands, suggesting a possible …

Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report

JM Michot, L Albiges, N Chaput, V Saada… - Annals of …, 2020 - annalsofoncology.org
1. Cooksley CD, Avritscher EBC, Bekele BN, et al. Epidemiology and outcomes of serious
influenza-related infections in the cancer population. Cancer. 2005; 104: 618e628. 2. …

Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study

A Italiano, JC Soria, M Toulmonde, JM Michot… - The Lancet …, 2018 - thelancet.com
Background Activating enhancer of zeste homolog 2 (EZH2) mutations or aberrations of the
switch/sucrose non-fermentable (SWI/SNF) complex (eg, mutations or deletions of the …

Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients

…, D Moro-Sibilot, JM Michot, J Raimbourg… - European …, 2017 - Eur Respiratory Soc
Immunotherapy is becoming a standard of care for many cancers. Immune-checkpoint
inhibitors (ICI) can generate immune-related adverse events. Interstitial lung disease (ILD) has …

Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors

E De Martin, JM Michot, B Papouin, S Champiat… - Journal of …, 2018 - Elsevier
Background & Aims Immunotherapy for metastatic cancer can be complicated by the onset
of hepatic immune-related adverse events (IRAEs). This study compared hepatic IRAEs …

Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma

…, CH Moskowitz, JM Michot, J Kuruvilla… - Blood, The Journal …, 2017 - ashpublications.org
J.-MM has received consulting fees from Bristol-Myers Squibb. JK has received research
funding from Roche; consultancy fees from Bristol-Myers Squibb, Gilead, Janssen, Roche, and …

Evaluation of readministration of immune checkpoint inhibitors after immune-related adverse events in patients with cancer

A Simonaggio, JM Michot, AL Voisin, J Le Pavec… - JAMA …, 2019 - jamanetwork.com
Importance Although immune checkpoint inhibitors (ICIs), such as anti–PD-1 (programmed
cell death 1) or anti–PD-L1 (programmed cell death 1 ligand 1), have proved effective in …